Trials / Completed
CompletedNCT02321475
EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders
Non-interventional Prospective Observational Study to Describe EGB 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 54 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness of EGb 761® (Tanakan®) in Russian patients of middle age and younger, suffering from psycho-emotional symptoms added to cognitive disorders based on the improvement of FAM test (feeling-healthy, activity, mood test) score.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EGb761® |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2014-12-22
- Last updated
- 2020-03-31
Locations
2 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT02321475. Inclusion in this directory is not an endorsement.